First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervic... (in environmentswith few amenities or hea...)

First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervical Disease

Date:9/21/2008

in environments with few amenities or healthcare staff. In this study, the careHPV test was effectively run by inexperienced, newly trained, minimally educated technicians under difficult conditions of temperature, humidity, lighting and space," said Attila Lorincz, PhD, senior author of the study and a professor of molecular epidemiology at Barts and the London School of Medicine, as well as London's Queen Mary College. "Another advantage of careHPV is that it can produce results within two and a half hours, allowing treatment to be administered during the same visit -- a critical requirement when women would likely not be able to return for follow-up care if sent home after their exam."

About HPV and cervical cancer (http://www.theHPVtest.com)

Cervical cancer affects nearly 500,000 women around the world every year and kills more than 300,000 -- of which 85 percent are in developing countries. After breast cancer, it is the second-most-common malignancy found in women. Cervical cancer is caused by "high-risk" types of the human papillomavirus (HPV), which are sexually transmitted. It's estimated that 80 percent of women will get an HPV infection at some point in their lives. However, in most cases, the infection goes away or is suppressed by the body without causing problems. It is only infections that persist that can cause abnormal cells to form that may develop into cervical cancer if not detected and treated early. One report from the World Health Organization estimates that only about 5 percent of women had been screened for cervical disease in the previous five years, compared to 40-50 percent in the developed world.

About QIAGEN (http://www.qiagen.com)

QIAGEN NV is the leading global provider of sample and assay technologies, with its global headquarters in the Netherlands. Sample technologies are used to isolate and process DN
'/>"/>

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Five-Year Data Confirm That Early Treatment with Betaseron(R) at First Sign of Disease Can Delay Progression to MS
2. MicroRNA First Disclosed by Rosetta Genomics may Increase Efficacy of Imatinib (Gleevec(R)(1)) in Glioblastoma
3. Eularis Releases First-Ever Study on ROI of Pre-Launch Named Patient Programmes
4. F.D.A. Approves SANCUSO(R), the First and Only Patch for Preventing Nausea and Vomiting in Cancer Patients Undergoing Chemotherapy
5. The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
6. CVBT Announces First Site to Begin Patient Enrollment for Its Phase II Heart Trial
7. FDA Approves First Hepatitis B Viral Load Test
8. Stem Cell Sciences Announces the Creation of the Worlds First Authentic Rat Embryonic Stem Cells from its Exclusively Licensed Technology
9. Biosensors DES Demonstrates Equivalent Safety and Efficacy to Industry Leading DES in First Real World, All Comers Clinical Study
10. CMS, Inc., an Elekta Company, Announces First Cancer Patients Treated With Monaco(TM) Radiation Treatment Planning System
11. Discharge of First U.S. DuraHeart(TM) Patient

Post Your Comments:

First Published Study of New HPV Test for Developing Countries Shows High Accuracy in Predicting Cervic...(in environmentswith few amenities or hea...),Health